PD-L1 copy number gain in nonsmall-cell lung cancer defines a new subset of patients for anti PD-L1 therapy.
Research Center Borstel, Borstel Airway Research Center North (ARCN), Member of the German Center for Lung Research, Großhansdorf tgoldmann@fz-borstel.de.
T
T
Goldmann
LungenClinic Grosshansdorf, Großhansdorf, Germany.
C
C
Kugler
Airway Research Center North (ARCN), Member of the German Center for Lung Research, Großhansdorf LungenClinic Grosshansdorf, Großhansdorf, Germany.
N
N
Reinmuth
Research Center Borstel, Borstel.
E
E
Vollmer
Airway Research Center North (ARCN), Member of the German Center for Lung Research, Großhansdorf LungenClinic Grosshansdorf, Großhansdorf, Germany.
M
M
Reck
D000230:Adenocarcinoma / Q000188:drug therapy / Q000235:genetics*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D060890:B7-H1 Antigen / Q000235:genetics*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000235:genetics; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000235:genetics*; D056915:DNA Copy Number Variations; D005260:Female; D005784:Gene Amplification; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D058990:Molecular Targeted Therapy
D000970:Antineoplastic Agents; D060890:B7-H1 Antigen; C423236:CD274 protein, human